Research suggests that patients who take Onglyza® (saxagliptin) for Type 2 diabetes may face an increased risk of heart failure.
If you or someone you love suffered severe or fatal heart problems after taking Onglyza, you may be eligible for compensation. We fight pharmaceutical companies when their negligence harms innocent people, and we're here to protect your rights. Call or fill out our free online form to get help now.
Onglyza® Increases Risk of Heart Failure
Onglyza was approved by the U.S. Food and Drug Administration (FDA) in 2009 to lower blood sugar in patients with Type 2 diabetes. Belonging to a class of diabetes drugs known as DPP-4 inhibitors, the drug is designed to help manage diabetes with no increased risk of hypoglycemia—or dangerously low blood sugar. Kombiglyze® XR, a combination of Onglyza and an older Type 2 diabetes drug, was approved one year later in 2010.
In October 2013, a study published in the New England Journal of Medicine revealed an increased risk of hospitalization for heart failure after taking saxagliptin.
The study prompted the FDA to issue a safety communication on February 11, 2014, stating it was investigating the link between Onglyza and the risk of heart failure.
In April 2015, an FDA advisory panel concluded that patients who take Onglyza face an increased risk of heart failure—a fatal condition in which the heart is weakened and can't pump enough blood to meet the body's needs.
According to FDA documents, one study showed a 27 percent increase in the rate of heart failure when taking Onglyza. As a result, members of the FDA advisory panel stated that the drug's labeling should be updated to warn of the heart failure risk.
Get Help With Your Onglyza® Lawsuit
You're not alone if you or someone you love suffered heart failure after taking Onglyza. Our drug injury lawyers have the experience it takes to help you get the compensation you need for your medical bills, lost wages, and pain and suffering.
Your time to take legal action is limited. Don't wait—call or contact us immediately to get started with your claim.
Onglyza® and Kombiglyze® XR are registered trademarks of AstraZeneca PLC and are used here only to identify the products in question
This law firm is not associated with, sponsored by, or affiliated with AstraZeneca PLC, Investor's Business Daily, The New England Journal of Medicine, or the U.S. Food and Drug Administration.